Sun pharmaceutical Industries Limited has officially announced its third-quarter results for FY26, demonstrating strong growth across multiple business segments and reinforcing its position as a leading global pharmaceutical company. The Board of Directors approved these results at their meeting held on January 31, 2026.

Financial Performance Overview

The company's consolidated financial results for Q3FY26 showcase robust performance across key metrics. Revenue growth was driven by strong performance in branded businesses across India, Emerging Markets, and Global Innovative Medicines.

Segment-wise Performance

India Formulations

The India Formulations business continued its strong momentum with sales of ₹49,986 million, registering growth of 16.2% year-on-year. This segment accounted for 32.3% of total consolidated sales. Sun Pharma maintains its leadership position as India's No. 1 pharmaceutical company, with market share increasing from 8.1% to 8.4% according to Pharmarack MAT December 2025 report. The company launched 12 new products during the quarter.

US Formulations

US Formulations sales reached US$477 million, showing marginal growth of 0.6%. The Innovative Medicines portfolio continued to grow, offsetting declines in the generics business. This segment represented approximately 27.5% of total consolidated sales.

Global Markets Performance

Emerging Markets formulations demonstrated strong growth with sales of US$337 million, up 21.6% year-on-year, accounting for 19.4% of total sales. Rest of World formulations also performed well with sales of US$296 million, growing 14.5% and representing 17.1% of consolidated sales.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, the company maintained consistent growth momentum:

Regulatory Filing and Corporate Actions

The Board of Directors approved an interim dividend of ₹11.00 per equity share of ₹1 each for FY26, representing an increase from the previous year's interim dividend of ₹10.50 per share. The record date for dividend entitlement is February 5, 2026, with payment scheduled on or before February 16, 2026.

The unaudited standalone and consolidated financial results were approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors.

Innovation and R&D Focus

Sun Pharma continues to invest significantly in research and development, with R&D expenditure of ₹8,928 million in Q3FY26, representing 5.8% of sales. The company's innovative R&D pipeline includes five novel entities in clinical stage, with 57 approved NDAs and 14 NDAs awaiting US FDA approval. The Global Innovative Medicines business achieved sales of US$423 million, including a US$55 million milestone payment, with ex-milestone sales growing 13.2%.

Management Commentary

Kirti Ganorkar, Managing Director, highlighted the well-rounded growth across all businesses, stating that the results demonstrate strong performance led by branded businesses in India, Emerging Markets, and Global Innovative Medicines. The company's innovative product offering has expanded with the launch of Unloxycyt in the US and introduction of Ilumya in India, bringing differentiated therapies closer to patients.

Sun pharmaceutical Industries Limited has executed a substantial block trade on the National Stock Exchange (NSE), marking significant trading activity in the pharmaceutical major's shares. The transaction represents one of the notable institutional deals in the Indian pharmaceutical sector.

Block Trade Details

The block trade transaction involved key parameters that highlight the scale of institutional activity:

Market Significance

Block trades represent large-volume transactions typically executed by institutional investors, mutual funds, or other significant market participants. These transactions are conducted outside the regular order book to prevent substantial price movements that could occur with such large volumes in the open market.

The execution price of ₹1607.40 per share reflects the prevailing market conditions at the time of the transaction. Such substantial block trades often indicate portfolio restructuring activities by institutional investors or strategic stake changes in the company.

Transaction Impact

The block trade involving nearly 1.73 million shares represents a significant volume of Sun Pharmaceutical Industries' equity changing hands through institutional channels. The ₹278.87 crore transaction value underscores the substantial financial commitment involved in this institutional activity.

Block trades are typically pre-negotiated transactions that allow large investors to execute substantial volumes without causing significant market disruption, making them an important mechanism for institutional trading in the Indian equity markets.